The pan HDAC inhibitor belinostat was FDA-approved for the treatment of PTCL in 2014 [139], and the pan HDAC inhibitor panobinostat gained accelerated approval in 2015 to treat multiple myeloma in combination with dexamethasone and the proteasome inhibitor bortezomib [140]. Here, HDAC9 is linked to plasma cell myeloma.